[go: up one dir, main page]

BRPI0712206A2 - tratamento do agonista de melatonina - Google Patents

tratamento do agonista de melatonina Download PDF

Info

Publication number
BRPI0712206A2
BRPI0712206A2 BRPI0712206-3A BRPI0712206A BRPI0712206A2 BR PI0712206 A2 BRPI0712206 A2 BR PI0712206A2 BR PI0712206 A BRPI0712206 A BR PI0712206A BR PI0712206 A2 BRPI0712206 A2 BR PI0712206A2
Authority
BR
Brazil
Prior art keywords
agonist treatment
melatonin agonist
melatonin
treatment
agonist
Prior art date
Application number
BRPI0712206-3A
Other languages
English (en)
Inventor
Birznieks Gunther
Phadke Deepak
H. Polymeropoulos Mihael
Original Assignee
Vanda Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38723632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0712206(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vanda Pharmaceuticals, Inc. filed Critical Vanda Pharmaceuticals, Inc.
Publication of BRPI0712206A2 publication Critical patent/BRPI0712206A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

TRATAMENTO DO AGONISTA DE MELATONINA. A presente invenção refere-se a métodos de administração de (1R-trans)-N-[[2-(2,3-diidro-4-benzofuraniI)ciclopropiI]metil]propanam ida como um agonista do receptor de melatonina a um ser humano para tratar ou prevenir um distúrbio do ritmo circadiano ou distúrbio do sono.
BRPI0712206-3A 2006-05-22 2007-05-22 tratamento do agonista de melatonina BRPI0712206A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74784706P 2006-05-22 2006-05-22
US60/747847 2006-05-22
PCT/US2007/069411 WO2007137244A1 (en) 2006-05-22 2007-05-22 Melatonin agonist treatment

Publications (1)

Publication Number Publication Date
BRPI0712206A2 true BRPI0712206A2 (pt) 2012-03-13

Family

ID=38723632

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0712206-3A BRPI0712206A2 (pt) 2006-05-22 2007-05-22 tratamento do agonista de melatonina

Country Status (17)

Country Link
US (7) US20090105333A1 (pt)
EP (1) EP2028937B2 (pt)
JP (5) JP2009538332A (pt)
KR (2) KR101571163B1 (pt)
AU (3) AU2007253701A1 (pt)
BR (1) BRPI0712206A2 (pt)
CA (2) CA2950087A1 (pt)
CY (1) CY1120433T1 (pt)
DK (1) DK2028937T4 (pt)
ES (1) ES2532849T5 (pt)
MX (1) MX2008014841A (pt)
NL (1) NL300795I2 (pt)
PL (1) PL2028937T5 (pt)
PT (1) PT2028937E (pt)
RU (1) RU2488392C2 (pt)
WO (1) WO2007137244A1 (pt)
ZA (1) ZA200809529B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2488392C2 (ru) † 2006-05-22 2013-07-27 Ванда Фармасьютиклз, Инк. Лечение агонистом мелатонина
EP2195462B1 (en) * 2007-09-13 2013-06-12 Vanda Pharmaceuticals Inc. Prediction of sleep parameter and response to sleep-inducing compound based on per3 vntr genotype
EP2453891A1 (en) * 2009-07-16 2012-05-23 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
RU2650647C2 (ru) 2012-01-26 2018-04-16 Ванда Фармасьютиклз Инк. Лечение нарушений циркадного ритма
BR112015014619A2 (pt) 2012-12-18 2017-07-11 Vanda Pharmaceuticals Inc tratamento de transtornos do ritmo circadiano
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
WO2015117048A1 (en) 2014-01-31 2015-08-06 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR20240015729A (ko) 2014-09-02 2024-02-05 반다 파마슈티칼즈, 인코퍼레이티드. 스미스 마제니스 증후군을 치료하기 위한 타시멜테온
US20210059973A1 (en) 2017-08-02 2021-03-04 Vanda Pharmaceuticals Inc. Treatment of Affective Disorders
WO2019173180A1 (en) * 2018-03-04 2019-09-12 Vanda Pharmaceuticals Inc. Treatment of disorders with tasimelteon
JP7432884B2 (ja) * 2018-03-26 2024-02-19 パナソニックＩｐマネジメント株式会社 サポートシステム、機器制御システム、サポートシステムの作動方法、及び、機器制御システムの作動方法
AU2019337627A1 (en) * 2018-09-12 2021-04-01 Vanda Pharmaceuticals Inc.. Improving sleep or post-sleep performance
EP3923929B1 (en) * 2019-02-13 2023-04-05 Vanda Pharmaceuticals Inc. Method of improving sleep
ES3020034T3 (en) * 2019-06-29 2025-05-21 Vanda Pharmaceuticals Inc Tasimelteon use in treating sleep aberrations
CA3161975A1 (en) 2019-12-13 2021-06-17 Vanda Pharmaceuticals Inc. Liquid tasimelteon formulations and methods of use thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126630B1 (en) * 1983-05-18 1987-09-16 Monash University The use of melatonin for the manufacture of a medicament
US5242941A (en) † 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
IT1251544B (it) * 1991-05-13 1995-05-17 Gabriele Biella Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico
GB9416884D0 (en) * 1994-08-20 1994-10-12 Danbiosyst Uk Drug delivery compositions
AU717180B2 (en) * 1995-03-06 2000-03-16 Novo Nordisk A/S Stimulation of meiosis
CA2274183C (en) * 1996-12-10 2006-10-24 Bristol-Myers Squibb Company Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US20050137247A1 (en) * 2003-12-22 2005-06-23 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
CA2551637A1 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
CA2616177C (en) * 2005-07-29 2012-05-01 Vanda Pharmaceuticals, Inc. Imidazolylalkyl-pyridines for the treatment of a sleep disorder
RU2488392C2 (ru) † 2006-05-22 2013-07-27 Ванда Фармасьютиклз, Инк. Лечение агонистом мелатонина
EP2195462B1 (en) * 2007-09-13 2013-06-12 Vanda Pharmaceuticals Inc. Prediction of sleep parameter and response to sleep-inducing compound based on per3 vntr genotype
US11918557B2 (en) * 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
RU2650647C2 (ru) * 2012-01-26 2018-04-16 Ванда Фармасьютиклз Инк. Лечение нарушений циркадного ритма
BR112015014619A2 (pt) * 2012-12-18 2017-07-11 Vanda Pharmaceuticals Inc tratamento de transtornos do ritmo circadiano
US10376487B2 (en) * 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
JP6921534B2 (ja) * 2014-02-12 2021-08-18 バンダ・ファーマシューティカルズ・インコーポレイテッドＶａｎｄａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 高純度医薬品等級タシメルテオン
KR20240015729A (ko) * 2014-09-02 2024-02-05 반다 파마슈티칼즈, 인코퍼레이티드. 스미스 마제니스 증후군을 치료하기 위한 타시멜테온
EP3212238A1 (en) † 2014-10-28 2017-09-06 Sandoz AG Pharmaceutical composition consisting of ceftaroline fosamil acetic acid solvate particles and arginine particles, both having a specific particle size distribution
US11013713B2 (en) * 2015-12-15 2021-05-25 Vanda Pharmaceuticals Inc. Method of treatment
EP3923929B1 (en) * 2019-02-13 2023-04-05 Vanda Pharmaceuticals Inc. Method of improving sleep
CA3161975A1 (en) * 2019-12-13 2021-06-17 Vanda Pharmaceuticals Inc. Liquid tasimelteon formulations and methods of use thereof

Also Published As

Publication number Publication date
EP2028937A1 (en) 2009-03-04
AU2013207585B2 (en) 2016-04-28
CY1120433T1 (el) 2019-07-10
CA2666293A1 (en) 2007-11-29
DK2028937T3 (en) 2015-04-07
AU2021273588A1 (en) 2021-12-16
AU2007253701A1 (en) 2007-11-29
KR101571163B1 (ko) 2015-11-23
JP2009538332A (ja) 2009-11-05
JP2015013875A (ja) 2015-01-22
PL2028937T3 (pl) 2015-10-30
KR20090034810A (ko) 2009-04-08
CA2950087A1 (en) 2007-11-29
ES2532849T3 (es) 2015-04-01
RU2488392C2 (ru) 2013-07-27
US20180243258A1 (en) 2018-08-30
KR101587394B1 (ko) 2016-01-21
US20200397741A1 (en) 2020-12-24
ES2532849T5 (es) 2018-10-18
AU2021273588B2 (en) 2023-03-02
US20090105333A1 (en) 2009-04-23
NL300795I2 (pt) 2017-03-28
JP6480050B2 (ja) 2019-03-06
MX2008014841A (es) 2008-12-05
JP6659072B2 (ja) 2020-03-04
US20240325339A1 (en) 2024-10-03
US20230021493A1 (en) 2023-01-26
JP2018109057A (ja) 2018-07-12
JP6306114B2 (ja) 2018-04-04
WO2007137244A1 (en) 2007-11-29
ZA200809529B (en) 2009-12-30
PL2028937T5 (pl) 2018-12-31
PT2028937E (pt) 2015-04-09
EP2028937B2 (en) 2018-06-27
RU2008150622A (ru) 2010-06-27
KR20150083932A (ko) 2015-07-20
EP2028937B1 (en) 2015-01-28
CA2666293C (en) 2017-01-10
JP2019089812A (ja) 2019-06-13
US20160354337A1 (en) 2016-12-08
EP2028937A4 (en) 2010-06-02
DK2028937T4 (en) 2018-09-03
JP2017031183A (ja) 2017-02-09
US20150080464A1 (en) 2015-03-19

Similar Documents

Publication Publication Date Title
BRPI0712206A2 (pt) tratamento do agonista de melatonina
EA201791669A3 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
MX2009013989A (es) Terapia en combinacion para depresion.
EA201190280A1 (ru) Производные l-(пиперидин-4-ил)пиразола в качестве модуляторов gpr 119
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
MX2010003949A (es) N-fenil-bipirrolidina carboxamidas sustituidas y uso terapeutico de las mismas.
UA96777C2 (ru) Фенилпропионамидные соединения и их применение как опиоидных агонистов
EA201300869A1 (ru) Морфинановые соединения
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
SI2205244T1 (sl) Postopki dajanja N-(5-terc.-butil-izoksazol-3-il)-N'-(4-(7-(2-morfolin- 4-il-etoksi-)imidazo-2,1-b)-(1,3)-benzotiazol-2-il)-fenil)sečnine za zdravljenje proliferativne bolezni
BRPI0607529A2 (pt) compostos de azol neuroterapêuticos
MX349754B (es) Metodo para la administracion de 4-((1r,3s)-6-cloro-3-fenil-indan- 1-il)-1,2,2-trimetil-piperazina y de sus sales en el tratamiento de esquinozofrenia.
MX2010013020A (es) Metodos y composiciones para trastornos del sueño y otros trastornos.
IL186200A (en) Use of amylin and agonists, analogues and derivatives of amylin for the preparation of a drug for the treatment of psychiatric illness
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
NO20064792L (no) Anvendelse av rotigotin til behandling og forbinding av Parkinsons pluss syndrom.
ATE356621T1 (de) (s)-2-n-propylamino-5-hydroxytetralin als d3- agonistisches therapeutikum
MX2010004003A (es) N-fenil-pirrolidinilmetlipirrolidin amidas sustituidas y uso terapeutico de las mismas.
MX2010003948A (es) N-fenil-birrolidin ureas sustituidas y uso terapeutico de las mismas.
GEP20196969B (en) New therapeutical composition containing apomorphine as active ingredient
BR112014031360A2 (pt) derivado de metil amina cíclica heteroaromática
MX2010004878A (es) Derivados de tioeter y eter heterociclico y metodos de uso de los mismos.
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
MX2011010782A (es) Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos.
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]